Siemens PETNET Solutions
Overview of PETNET Solutions
PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., operates the world's largest network of PET radiopharmaceutical drug manufacturing facilities and dispensing nuclear pharmacies with over 50 locations worldwide.
These facilities manufacture and dispense PET drug products for hospitals, clinics and research facilities. As part of Siemens Molecular Imaging, PETNET Solutions services complement the most comprehensive molecular imaging portfolio in the industry, which includes imaging equipment for clinical settings and preclinical research, cyclotrons, radiochemistry modules and investigational imaging biomarkers. This relationship places PETNET on the cutting edge by providing new molecular imaging biomarkers to the PET community.
Delivering quality molecular imaging biomarkers
PETNET Solutions is the only company to offer a complete imaging biomarker value chain that encompasses discovery, clinical trials, manufacturing and dose dispensing capabilities.
PETNET Solutions delivers high-quality PET radiopharmaceuticals. As part of our best-in-class quality process, PETNET Solutions has standardized equipment and processes to ensure consistent products from all sites throughout the world. Every dose distributed is guaranteed to meet the applicable pharmacopeial standards for product quality and purity from production to labeled expiration time.
On-time and reliable delivery of imaging products is essential for the successful operation of a molecular imaging practice. PETNET Solutions has carefully planned and successfully built the SafetyNet, a unique program by which delivery of PET radiopharmaceuticals is guaranteed and on-time through our national network of PET radiopharmacies. Below is a listing of some of the products delivered through PETNET’s SafetyNet.
Additional biomarkers available – check with your local pharmacy.
Expanding the value of molecular imaging
In today’s competitive environment, it is essential to get the most from your investment. Our deep level of understanding and commitment to the evolving industry of molecular imaging makes our company much more than a network of PET drug manufacturing establishments and dispensing radiopharmacies.
Business development – support from trained dedicated experts with years of experience in molecular imaging with knowledge of local market activity to provide a comprehensive business view of your area.
MI LifeNet – an education and practice management online tool that fosters an important link between patients, physicians and nuclear pharmacists. MI LifeNet combines educational tools, outreach, reimbursement and practice management resources into one comprehensive program, providing you with a powerful set of resources to manage patients and your practice.
MI University – ultimate molecular imaging online training resource for PET/CT and SPECT/CT hybrid imaging. It provides you access to molecular imaging cases, protocols and techniques for SPECT/CT and PET/CT procedures, interactive web community and abstract database.
Taking it to the Streets® in-person training program that allows you to continuously expand your practice by increasing the knowledge of your marketing staff to PET/CT, understand the benefits for patients, educate them on the appropriate utilization of PET/CT and support the creation of outreach strategies for referring physicians.
Advancing a new paradigm for molecular imaging
As a global leader in PET radiopharmaceutical services, PETNET Solutions is the only company with a complete imaging biomarker value chain that encompasses discovery, clinical trials, manufacturing and nuclear pharmacy services capabilities. The combination of PETNET Solutions collaborations with the world’s leading research organizations and pharmaceutical companies creates one of the largest global clinical trial networks. Standardized equipment and processes at all our global facilities and clinical trial support services to our customers makes PETNET Solutions the ideal partner for clinical trials. This provides value to our customers by providing them access to new imaging biomarkers once approved for clinical use to continuously grow their business.